Jagoda Szkudlarek
PC37 – Jagoda Szkudlarek
Poznan University of Medical Sciences, Chair and Department of Pharmaceutical Chemistry, Poznań, Poland
Doctoral School, Poznan University of Medical Sciences, Poznań, Poland
jszkudlarek@ump.edu.pl
| Cationic Liposomes Co-Loaded With Cannabidiol and Additional Natural Bioactive Compounds for In Vitro Evaluation Against Glioblastoma Multiforme |
| Szkudlarek Jagoda1,2, Piwowarczyk Ludwika1, Krajka-Kuzniak Violetta3, Majchrzak-Celińska Aleksandra3, and Jelińska Anna1 1 Poznan University of Medical Sciences, Chair and Department of Pharmaceutical Chemistry, Rokietnicka 3, 60‑803 Poznań, Poland 2 Doctoral School, Poznan University of Medical Sciences, 70 Bukowska, 60-812 Poznań, Poland 3 Chair and Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 3 Rokietnicka, 60-806 Poznań, Poland |
| Abstract Glioblastoma multiforme is a highly aggressive brain tumor associated with poor clinical outcomes. Despite advances in standard therapies, treatment efficacy remains limited, prompting the search for new therapeutic strategies [1]. Natural compounds have emerged as promising candidates due to their diverse biological activities, but their clinical application is often restricted by limited bioavailability [2]. In this setting, nanocarrier-based delivery systems, particularly liposomes, offer an attractive approach by improving drug stability, enhancing bioavailability, and facilitating more effective transport of therapeutic agents to tumor tissue [3]. In this study, cationic liposomes were developed as carriers for cannabidiol (CBD) co-encapsulated with additional natural compounds for in vitro evaluation against glioma cells. The formulations were prepared by the thin-film hydration method, followed by extrusion to obtain more uniform vesicles. Physicochemical characterization included particle size, polydispersity index, and zeta potential measurements. Anticancer activity was assessed in U-138 MG cells using the MTT assay after 24 and 48 h of incubation, with non-cancer cells used as a reference. Liposomal systems showed nanoscale particle size, low polydispersity, and positive zeta potential. In vitro studies demonstrated that co-loaded formulations reduced glioma cell viability more effectively than the empty carrier, particularly after longer incubation. One of the co-loaded formulations showed a stronger antiproliferative effect in U-138 MG cells compared with the other formulation. Overall, cationic liposomes appear to be promising carriers for CBD-based combination therapy in glioblastoma and warrant further investigation. |
| References [1] Weller, M.; Wen, P.Y.; Chang, S.M.; Dirven, L.; Lim, M.; Monje, M.; Reifenberger, G. Glioma. Nat Rev Dis Primers. 2024, 10(1), 33. [2] Ożarowski, M.; Karpiński, T.M.; Czerny, B.; Kamiński, A.; Seremak-Mrozikiewicz, A. Plant alkaloids as promising anticancer compounds with blood-brain barrier penetration in the treatment of glioblastoma: in vitro and in vivo models. Molecules 2025, 30(7), 1561. [3] Haseeb, M.; Khan, I.; Kartal, Z.; Mahfooz, S.; Hatiboglu, M.A. Status quo in the liposome-based therapeutic strategies against glioblastoma: “targeting the tumor and tumor microenvironment”. Int J Mol Sci. 2024, 25(20), 11271. |